Personalized Cytokine-Directed Therapy With Tocilizumab for Refractory Immune Checkpoint Inhibitor–Related Cholangiohepatitis

For patients with corticosteroid (CS)-refractory immune checkpoint inhibitor–related cholangiohepatitis (irCH), no consensus exists regarding treatment, and outcomes remain poor. We evaluated the possibility of personalized treatment according to the patient’s cytokine profile and the immunohistopathologic assessment of the predominant immune infiltrate type of liver tissue.